Bansisons Tea Industries Limited, now operating as Novyra Pharmachem Limited, conducted its independent directors meeting on March 20, 2026, at its registered office in Surat, Gujarat. The meeting was held in compliance with Regulation 25(3) of the Securities and Exchange Board of India (LODR) Regulations, 2015, read with Schedule IV of the Companies Act, 2013.

Meeting Details and Duration

The independent directors meeting was conducted for the Financial Year 2025-26, commencing at 01.00 P.M. and concluding at 06.45 P.M. The extended duration reflects the comprehensive nature of the governance review undertaken by the independent directors.

Key Agenda Items Reviewed

The independent directors addressed three critical governance areas during their meeting. The comprehensive review process encompassed multiple aspects of board effectiveness and corporate governance standards.

The meeting agenda included:

• Review of performance of non-independent directors and the board of directors as a whole
• Assessment of the chairperson's performance, incorporating feedback from both executive and non-executive directors
• Evaluation of information flow quality, quantity, and timeliness between management and the board of directors

Regulatory Compliance and Corporate Governance

The meeting fulfills the company's statutory obligations under SEBI regulations, ensuring adherence to corporate governance standards. The independent directors' assessment of information flow between management and the board is particularly significant for ensuring effective board functioning.

Company Information

Novyra Pharmachem Limited operates from its registered office located at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, Vastadevadi Road, Surat, Gujarat. The company maintains its BSE listing under scrip code 519353 and continues to operate under CIN L21001GJ1987PLC171085.

The meeting outcome was communicated to BSE Limited as part of the company's disclosure obligations under Regulation 30 of SEBI LODR Regulations, ensuring transparency with stakeholders and regulatory authorities.

Novyra Pharmachem Limited has announced a key leadership appointment following its board meeting held on February 6, 2026. The company, formerly known as Bansisons Tea Industries Limited, approved the appointment of a new Additional Director during the meeting that concluded at 5:30 p.m.

Board Meeting Outcome

The board meeting, which commenced at 4:30 p.m. on February 6, 2026, resulted in the appointment of Anilkumar Mohanbhai Amreliya (DIN: 11339148) as Additional Director (Executive Director) of the company. The appointment is effective from February 6, 2026, and the director will hold office until the ensuing Annual General Meeting.

Director Profile and Experience

Mr. Amreliya brings extensive business experience to the role, having been engaged in business operations with over 25 years of expertise in sales and marketing. His professional background includes directorships in other companies, specifically Vaidehi Healthcare Private Limited and Vaid Super Specialty Hospital Private Limited.

Regulatory Compliance and Disclosures

The company has made comprehensive disclosures in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key regulatory confirmations include:

• The director does not hold more than 2% voting power in any companies
• He does not hold any shares of the company
• No relationships exist between directors
• The director is not debarred from holding directorial office by SEBI or any other authority

Company Information

Novyra Pharmachem Limited, with CIN L21001GJ1987PLC171085, operates from its registered office located at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, B/h Zenith Mill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat. The appointment reflects the company's ongoing efforts to strengthen its leadership team with experienced professionals in key operational areas.